Table 2 Azaindole-based FLT3 inhibitors
Compound name and its structure | Description | Refs. | |
|---|---|---|---|
| Target | FLT-3, GSK-3β, and VEGFR-2 | [73] |
Protein kinases (IC50) | 18, 9, and 48 nM, respectively | ||
In vitro cell viability percentage | 4.4% at a concentration of 52 μM, 2.40% at a concentration of 50 μM (in HT-29 (human colon adenocarcinoma cells), and, Molm-14 AML cells, respectively) | ||
| Target | FLT3-ITD, CSF1R, and KIT | |
Binding mode to FLT3 kinase | Type II | ||
Protein kinases’ Potency (IC50) | 11, 13, and 27 nM/L, respectively | ||
| Target | FLT3 | [72] |
Binding mode to FLT3 kinase | Type II | ||
FLT3 Potency (pIC50) | 8.02 | ||
| Target | FLT3 | [72] |
Binding mode to FLT3 kinase | Type I and II | ||
FLT3 Potency (pIC50) | 9.49 | ||
